As the COVID-19 pandemic rapidly spread across the globe in 2020, Sanofi considered a range of options to attack COVID-19, forging strategic partnerships to pool science, expertise and resources. Today, with more information on the virus, it has become clear that the most effective way to a post-pandemic world are safe and effective vaccines.
Sanofi is developing two vaccine candidates
Adjuvanted recombinant protein-based vaccine candidate: where do we stand?
Messenger RNA vaccine candidate: where do we stand?
Developed in partnership with Translate Bio, the project is on track to start phase 1/2 clinical trials in early 2021.
Scaling up manufacturing facilities
Supply agreements have already been agreed with the US, UK, EU and Canada and the company will also supply to the COVAX Facility, a collaboration led by the WHO and GAVI that aims to secure successful and equitable access to COVID-19 vaccines worldwide.
Reality safety check
While the urgency of developing an effective vaccine cannot be ignored, Sanofi’s top priority is safety. Our CEO, Paul Hudson, pledged with eight other biopharma CEOs to develop potential vaccines in accordance with high ethical standards and sound scientific principles regarding clinical trials and manufacturing processes.
Only vaccines that have passed an approved phase 3 trial will be submitted for approval or emergency-use authorization, a pledge that “will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved.”
“Our work, as always, is driven by science and our sense of responsibility,” said Paul.
Solidarity is key to moving the fight against COVID-19 forward and, in time, to establishing a blueprint for collaboration and preparation for future pandemics.